4884 — Kringle Pharma Income Statement
0.000.00%
Last trade - 00:00- ¥6bn
- ¥4bn
- ¥80m
Annual income statement for Kringle Pharma, fiscal year end - September 30th, JPY millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 468 | 290 | 392 | 69.3 | 80 |
| Cost of Revenue | |||||
| Gross Profit | 468 | 218 | 303 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 639 | 648 | 818 | 958 | 898 |
| Operating Profit | -172 | -358 | -426 | -889 | -818 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -116 | -300 | -330 | -853 | -755 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -118 | -301 | -332 | -854 | -756 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -118 | -301 | -332 | -854 | -756 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -118 | -301 | -332 | -854 | -756 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -107 | -72.5 | -68.3 | -158 | -118 |
| Dividends per Share |